Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Kura Oncology, Inc. (KURA : NSDQ)
 
 • Company Description   
Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California.

Number of Employees: 192

 
 • Price / Volume Information   
Yesterday's Closing Price: $10.39 Daily Weekly Monthly
20 Day Moving Average: 1,549,095 shares
Shares Outstanding: 87.02 (millions)
Market Capitalization: $904.11 (millions)
Beta: 0.25
52 Week High: $12.49
52 Week Low: $5.41
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -13.27% -13.12%
12 Week 1.37% -0.27%
Year To Date 0.00% 0.00%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
4930 DIRECTORS PLACE SUITE 500
-
SAN DIEGO,CA 92121
USA		 ph: 858-500-8800
fax: -		 ir@kuraoncology.com http://www.kuraoncology.com
 
 • General Corporate Information   
Officers
Troy E. Wilson - President and Chief Executive Officer
Thomas Doyle - Senior Vice President
Helen Collins - Director
Faheem Hasnain - Director
Thomas Malley - Director

Peer Information
Kura Oncology, Inc. (CORR.)
Kura Oncology, Inc. (RSPI)
Kura Oncology, Inc. (CGXP)
Kura Oncology, Inc. (BGEN)
Kura Oncology, Inc. (GTBP)
Kura Oncology, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 50127T109
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 02/25/26
Share - Related Items
Shares Outstanding: 87.02
Most Recent Split Date: (:1)
Beta: 0.25
Market Capitalization: $904.11 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.46 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.11 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 15.01% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 02/25/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.72
Price/Cash Flow: -
Price / Sales: 8.69
EPS Growth
vs. Year Ago Period: -34.92%
vs. Previous Quarter: -13.33%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 35.73%
ROE
12/31/25 - -
09/30/25 - -65.42
06/30/25 - -52.32
ROA
12/31/25 - -
09/30/25 - -30.59
06/30/25 - -29.59
Current Ratio
12/31/25 - -
09/30/25 - 5.12
06/30/25 - 6.16
Quick Ratio
12/31/25 - -
09/30/25 - 5.12
06/30/25 - 6.16
Operating Margin
12/31/25 - -
09/30/25 - -208.48
06/30/25 - -
Net Margin
12/31/25 - -
09/30/25 - -208.48
06/30/25 - -
Pre-Tax Margin
12/31/25 - -
09/30/25 - -206.33
06/30/25 - -234.07
Book Value
12/31/25 - -
09/30/25 - 2.79
06/30/25 - 3.53
Inventory Turnover
12/31/25 - -
09/30/25 - -
06/30/25 - -
Debt-to-Equity
12/31/25 - -
09/30/25 - 0.02
06/30/25 - 0.02
Debt-to-Capital
12/31/25 - -
09/30/25 - 2.15
06/30/25 - 2.09
 

Powered by Zacks Investment Research ©